Similarly, miR-216a and miR-216b are significantly downregulated in patient serum [69] and are known to inhibit oncogenic pathways across multiple tumor types by targeting KRAS, IGF2BP2, eIF4B, and ZEB1 [70,71,72]. Here, ZEB1 is linked to neoplasm.